Oral presentation highlights safe, robust reduction in apoC-III and triglycerides by MB-111, paving the way to the clinic in 2026.
MB-111 is a potential first-in-class, single-dose in vivo CRISPR gene editing therapy for persistent chylomicronemia Oral presentation highlights safe, robust, and durable reduction of apoC-III ...
Stunning success in halting Huntington's disease with gene therapy offers new hope to those with the disorder—and potential ...
Editas Medicine Inc. (NASDAQ:EDIT) is one of the best performing penny stocks to buy now. On September 5, HC Wainwright ...
Umoja Biopharma, the clinical-stage leader of in vivo cell therapies that aim to realize the full reach and promise of CAR T cells, ...
Effective blood clotting is crucial after blood vessel damage, but this process may be inefficient in some individuals due to hereditary factors. For instance, Hemophilia B is caused by a deficiency ...
Athernal Bio today announced its official launch alongside £3.5 million funding from founding investor Delin Ventures. The company is focused on the development of targeted immunotherapies for ...
Becoming a millionaire through stock investing is possible, but it requires patience, discipline, and the acumen to make informed investment choices. Not every company can generate the kind of returns ...
Glypican-3 (GPC3) has emerged as a promising immunotherapeutic target for hepatocellular carcinoma (HCC). However, its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback